

# UNITED STATES PATENT AND TRADEMARK OFFICE



UNITED STATES DEPARTMENT OF COMMERCE United States Patent and Trademark Office Address: COMMISSIONER FOR PATENTS P.O. Box 1450 Alexandria, Virginia 22313-1450 www.uspto.gov

| APPLICATION NO.                   | FI         | ILING DATE | FIRST NAMED INVENTOR | ATTORNEY DOCKET NO.     | CONFIRMATION NO. |
|-----------------------------------|------------|------------|----------------------|-------------------------|------------------|
| 09/830,666                        | 07/30/2001 |            | Nico J.M. Rijkhoff   | P66606USO 9516          |                  |
| 136                               | 7590       | 09/08/2003 |                      |                         |                  |
|                                   |            | IAN PLLC   | EXAMINER             |                         |                  |
| 400 SEVENTH STREET N.W. SUITE 600 |            |            |                      | OROPEZA, FRANCES P      |                  |
| WASHINGTON, DC 20004              |            |            |                      | ART UNIT                | PAPER NUMBER     |
|                                   |            |            |                      | 3762                    |                  |
|                                   |            |            |                      | DATE MAILED: 09/08/2003 | 9                |

Please find below and/or attached an Office communication concerning this application or proceeding.

|   | Application No.                   | Applicant(s)    |  |  |  |  |  |
|---|-----------------------------------|-----------------|--|--|--|--|--|
| Office Action Summers   | 09/830,666                        | RIJKHOFF ET AL. |  |  |  |  |  |
| Office Action Summary   | Examiner                          | Art Unit        |  |  |  |  |  |
|   | Frances P. Oropeza                | 3762            |  |  |  |  |  |
| The MAILING DATE of this communication appears on the cover sheet with the correspondence address<br>Period for Reply   |                                   |                 |  |  |  |  |  |
| A SHORTENED STATUTORY PERIOD FOR REPLY IS SET TO EXPIRE 3 MONTH(S) FROM THE MAILING DATE OF THIS COMMUNICATION.  - Extensions of time may be available under the provisions of 37 CFR 1.136(a). In no event, however, may a reply be timely filed after SIX (6) MONTHS from the mailing date of this communication.  - If the period for reply specified above is less than thirty (30) days, a reply within the statutory minimum of thirty (30) days will be considered timely.  - If NO period for reply is specified above, the maximum statutory period will apply and will expire SIX (6) MONTHS from the mailing date of this communication.  - Failure to reply within the set or extended period for reply will, by statute, cause the application to become ABANDONED (35 U.S.C. § 133).  - Any reply received by the Office later than three months after the mailing date of this communication, even if timely filed, may reduce any earned patent term adjustment. See 37 CFR 1.704(b).  Status |                                   |                 |  |  |  |  |  |
| 1) Responsive to communication(s) filed on 8/4/0  | 03 (Election)                     |                 |  |  |  |  |  |
| 2a) ☐ This action is <b>FINAL</b> . 2b) ☑ Thi   | s action is non-final.            |                 |  |  |  |  |  |
| 3) Since this application is in condition for allowance except for formal matters, prosecution as to the merits is closed in accordance with the practice under <i>Ex parte Quayle</i> , 1935 C.D. 11, 453 O.G. 213. <b>Disposition of Claims</b>   |                                   |                 |  |  |  |  |  |
| 4)⊠ Claim(s) <u>22-39</u> is/are pending in the application.  |                                   |                 |  |  |  |  |  |
| 4a) Of the above claim(s) <u>30-39</u> is/are withdrawn from consideration.   |                                   |                 |  |  |  |  |  |
| 5) Claim(s) is/are allowed.   |                                   |                 |  |  |  |  |  |
| 6)⊠ Claim(s) <u>22-29</u> is/are rejected.  |                                   |                 |  |  |  |  |  |
| 7) Claim(s) is/are objected to.   |                                   |                 |  |  |  |  |  |
| 8) Claim(s) are subject to restriction and/or   | r election requirement.           |                 |  |  |  |  |  |
| Application Papers  |                                   |                 |  |  |  |  |  |
| 9)⊠ The specification is objected to by the Examiner.   |                                   |                 |  |  |  |  |  |
| 10)⊠ The drawing(s) filed on <u>30 July 2001</u> is/are: a)□ accepted or b)⊠ objected to by the Examiner.   |                                   |                 |  |  |  |  |  |
| Applicant may not request that any objection to the drawing(s) be held in abeyance. See 37 CFR 1.85(a).   |                                   |                 |  |  |  |  |  |
| 11) ☐ The proposed drawing correction filed on is: a) ☐ approved b) ☐ disapproved by the Examiner.  |                                   |                 |  |  |  |  |  |
| If approved, corrected drawings are required in reply to this Office action.  |                                   |                 |  |  |  |  |  |
| 12) The oath or declaration is objected to by the Examiner.   |                                   |                 |  |  |  |  |  |
| Priority under 35 U.S.C. §§ 119 and 120   |                                   |                 |  |  |  |  |  |
| 13) Acknowledgment is made of a claim for foreign priority under 35 U.S.C. § 119(a)-(d) or (f).   |                                   |                 |  |  |  |  |  |
| a) ☐ All b) ☐ Some * c) ☑ None of:  |                                   |                 |  |  |  |  |  |
| 1. Certified copies of the priority documents   | s have been received.             |                 |  |  |  |  |  |
| 2. Certified copies of the priority documents   | s have been received in Applicati | on No           |  |  |  |  |  |
| <ul> <li>3. Copies of the certified copies of the priority documents have been received in this National Stage application from the International Bureau (PCT Rule 17.2(a)).</li> <li>* See the attached detailed Office action for a list of the certified copies not received.</li> </ul>   |                                   |                 |  |  |  |  |  |
| 14) Acknowledgment is made of a claim for domestic priority under 35 U.S.C. § 119(e) (to a provisional application).  |                                   |                 |  |  |  |  |  |
| a) The translation of the foreign language provisional application has been received.  15) Acknowledgment is made of a claim for domestic priority under 35 U.S.C. §§ 120 and/or 121.   |                                   |                 |  |  |  |  |  |
| Attachment(s)   |                                   |                 |  |  |  |  |  |
| 1) Notice of References Cited (PTO-892) 2) Notice of Draftsperson's Patent Drawing Review (PTO-948) 3) Information Disclosure Statement(s) (PTO-1449) Paper No(s) 5.    Interview Summary (PTO-413) Paper No(s)   Notice of Informal Patent Application (PTO-152)   Other:  |                                   |                 |  |  |  |  |  |
| S. Patent and Trademark Office  |                                   |                 |  |  |  |  |  |

Art Unit: 3762

### **DETAILED ACTION**

#### Election/Restrictions

1. Claims 30-39 are withdrawn from further consideration pursuant to 37 CFR 1.142(b) as being drawn to a nonelected invention, there being no allowable generic or linking claim. The election was made without traverse in Paper No. 8.

### **Drawings**

- 2. The drawings are objected to because figure 1 and 2 contain a title of "Bladder patent" that is superfluous; this title should be deleted.
- 3. Figure 3 objected to under 37 CFR 1.83(a) because the rectangular boxes, (44) and (45), are not labeled as described in the specification. Any structural detail that is essential for a proper understanding of the disclosed invention should be shown in the drawing. MPEP § 608.02(d). A proposed drawing correction or corrected drawings are required in reply to the Office action to avoid abandonment of the application. The objection to the drawings will not be held in abeyance.

## Specification

4. The specification is objected to because it does not include section headings.

The following guidelines illustrate the preferred layout for the specification of a utility application. These guidelines are suggested for the applicant's use.

## Arrangement of the Specification

As provided in 37 CFR 1.77(b), the specification of a utility application should include the following sections in order. Each of the lettered items should appear in upper case, without underlining or bold type, as a section heading. If no text follows the section heading, the phrase "Not Applicable" should follow the section heading:

- (a) TITLE OF THE INVENTION.
- (b) CROSS-REFERENCE TO RELATED APPLICATIONS.

. . . . .

Art Unit: 3762

(c) STATEMENT REGARDING FEDERALLY SPONSORED RESEARCH OR DEVELOPMENT.

- (d) INCORPORATION-BY-REFERENCE OF MATERIAL SUBMITTED ON A COMPACT DISC (See 37 CFR 1.52(e)(5) and MPEP 608.05. Computer program listings (37 CFR 1.96(c)), "Sequence Listings" (37 CFR 1.821(c)), and tables having more than 50 pages of text are permitted to be submitted on compact discs.) or
  - REFERENCE TO A "MICROFICHE APPENDIX" (See MPEP § 608.05(a). "Microfiche Appendices" were accepted by the Office until March 1, 2001.)
- (e) BACKGROUND OF THE INVENTION.
  - (1) Field of the Invention.
  - (2) Description of Related Art including information disclosed under 37 CFR 1.97- 1.98.
- (f) BRIEF SUMMARY OF THE INVENTION.
- (g) BRIEF DESCRIPTION OF THE SEVERAL VIEWS OF THE DRAWING(S).
- (h) DETAILED DESCRIPTION OF THE INVENTION.
- (i) CLAIM OR CLAIMS (commencing on a separate sheet).
- (i) ABSTRACT OF THE DISCLOSURE (commencing on a separate sheet).
- (k) SEQUENCE LISTING (See MPEP § 2424 and 37 CFR 1.821-1.825. A "Sequence Listing" is required on paper if the application discloses a nucleotide or amino acid sequence as defined in 37 CFR 1.821(a) and if the required "Sequence Listing" is not submitted as an electronic document on compact disc).

### **Content of Specification**

- (a) <u>Title of the Invention</u>: See 37 CFR 1.72(a) and MPEP § 606. The title of the invention should be placed at the top of the first page of the specification unless the title is provided in an application data shet. The title of the invention should be brief but technically accurate and descriptive, preferably from two to seven words may not contain more than 500 characters.
- (b) <u>Cross-References to Related Applications</u>: See 37 CFR 1.78 and MPEP § 201.11.
- (c) <u>Statement Regarding Federally Sponsored Research & Development</u>: See MPEP § 310.
- (d) Incorporation-By-Reference Of Material Submitted On a Compact Disc: The specification is required to include an incorporation-by-reference of electronic documents that are to become part of the permanent United States Patent and Trademark Office records in the file of a patent application. See 37 CFR 1.52(e) and MPEP § 608.05. Computer program listings (37 CFR 1.96(c)), "Sequence Listings" (37 CFR 1.821(c)), and tables having more than 50 pages of text were permitted as electronic documents on compact discs beginning on 9/8/2000.

Application/Control Number: 09/830,666

Or alternatively, <u>Reference to a "Microfiche Appendix</u>": See MPEP § 608.05(a). "Microfiche Appendices" were accepted by the Office until March 1, 2001.

- (e) <u>Background of the Invention</u>: See MPEP § 608.01(c). The specification should set forth the Background of the Invention in two parts:
  - (1) <u>Field of the Invention</u>: A statement of the field of art to which the invention pertains. This statement may include a paraphrasing of the applicable U.S. patent classification definitions of the subject matter of the claimed invention. This item may also be titled "Technical Field."
  - (2) Description of the Related Art including information disclosed under 37

    CFR 1.97 and 37 CFR 1.98: A description of the related art known to the applicant and including, if applicable, references to specific related art and problems involved in the prior art which are solved by the applicant's invention. This item may also be titled "Background Art."
- (f) Brief Summary of the Invention: See MPEP § 608.01(d). A brief summary or general statement of the invention as set forth in 37 CFR 1.73. The summary is separate and distinct from the abstract and is directed toward the invention rather than the disclosure as a whole. The summary may point out the advantages of the invention or how it solves problems previously existent in the prior art (and preferably indicated in the Background of the Invention). In chemical cases it should point out in general terms the utility of the invention. If possible, the nature and gist of the invention or the inventive concept should be set forth. Objects of the invention should be treated briefly and only to the extent that they contribute to an understanding of the invention.
- (g) <u>Brief Description of the Several Views of the Drawing(s)</u>: See MPEP § 608.01(f). A reference to and brief description of the drawing(s) as set forth in 37 CFR 1.74.
- (h) Detailed Description of the Invention: See MPEP § 608.01(g). A description of the preferred embodiment(s) of the invention as required in 37 CFR 1.71. The description should be as short and specific as is necessary to describe the invention adequately and accurately. Where elements or groups of elements, compounds, and processes, which are conventional and generally widely known in the field of the invention described and their exact nature or type is not necessary for an understanding and use of the invention by a person skilled in the art, they should not be described in detail. However, where particularly complicated subject matter is involved or where the elements, compounds, or processes may not be commonly or widely known in the field, the specification should refer to another patent or readily available publication which adequately describes the subject matter.

Art Unit: 3762

(i) Claim or Claims: See 37 CFR 1.75 and MPEP § 608.01(m). The claim or claims must commence on separate sheet or electronic page (37 CFR 1.52(b)(3)). Where a claim sets forth a plurality of elements or steps, each element or step of the claim should be separated by a line indentation. There may be plural indentations to further segregate subcombinations or related steps. See 37 CFR 1.75 and MPEP § 608.01(i)-(p).

- (j) Abstract of the Disclosure: See MPEP § 608.01(f). A brief narrative of the disclosure as a whole in a single paragraph of 150 words or less commencing on a separate sheet following the claims. In an international application which has entered the national stage (37 CFR 1.491(b)), the applicant need not submit an abstract commencing on a separate sheet if an abstract was published with the international application under PCT Article 21. The abstract that appears on the cover page of the pamphlet published by the International Bureau (IB) of the World Intellectual Property Organization (WIPO) is the abstract that will be used by the USPTO. See MPEP § 1893.03(e).
- (k) <u>Sequence Listing.</u> See 37 CFR 1.821-1.825 and MPEP §§ 2421-2431. The requirement for a sequence listing applies to all sequences disclosed in a given application, whether the sequences are claimed or not. See MPEP § 2421.02.

Appropriate correction is required.

- 5. The specification contains the following typographical or grammatical errors:
  - Page 1 the title is not properly capitalized and contains a period,
  - Page 1 line 35, "prevent the detrusor muscle to contact" is not clear,
  - Page 2 line 17, it appears "continues" should be --continuous--,
  - Page 2 lines 20-30, the reference information should be removed,
  - Page 3, lines 17-24 the sentence is incomplete,
  - Page 4, line 12 it appears "Primalarythe" should be -- Primarily the--,
  - Page 4, line 16 "continuos" should be --continuous--, and
  - Page 10 the list of reference numeral is superfluous and should be deleted.

Appropriate correction is required.

Art Unit: 3762

## Claim Objections

6. Claim 28 is objected to because in line 2 it appears "is" should be --are--. Appropriate correction is required.

7. The claims should begin with the phrase --We claim:--, --What is claimed is:--, or equivalent. Appropriate correction is required.

### Abstract

8. The abstract of the disclosure is objected to because of the phrases: "This application concerns", "which sensor", and "means for stimulation of nerves".

The Applicant is reminded of the proper language and format for an abstract of the disclosure. The abstract should be in narrative form and generally limited to a single paragraph on a separate sheet within the range of 50 to 150 words. It is important that the abstract not exceed 150 words in length since the space provided for the abstract on the computer tape used by the printer is limited. The form and legal phraseology often used in patent claims, such as "means" and "said," should be avoided. The abstract should describe the disclosure sufficiently to assist readers in deciding whether there is a need for consulting the full patent text for details. The language should be clear and concise and should not repeat information given in the title. It should avoid using phrases which can be implied, such as, "The disclosure concerns," "The disclosure defined by this invention," "The disclosure describes," etc. Correction is required. See MPEP § 608.01(b).

Art Unit: 3762

### Claim Rejections - 35 USC § 112

9. The following is a quotation of the second paragraph of 35 U.S.C. 112:

The specification shall conclude with one or more claims particularly pointing out and distinctly claiming the subject matter which the applicant regards as his invention.

Claim 25 is rejected under 35 U.S.C. 112, second paragraph, as being indefinite for failing to particularly point out and distinctly claim the subject matter which applicant regards as the invention.

Claim 25 is unclear because in line 2 it appears "a detrusor contraction" should be --the detrusor contraction--.

In claim 25, "the first signals" and "the second signals" lack antecedent basis.

Appropriate correction is required.

### Claim Rejections - 35 USC § 103

- 10. The following is a quotation of 35 U.S.C. 103(a) which forms the basis for all obviousness rejections set forth in this Office action:
  - (a) A patent may not be obtained though the invention is not identically disclosed or described as set forth in section 102 of this title, if the differences between the subject matter sought to be patented and the prior art are such that the subject matter as a whole would have been obvious at the time the invention was made to a person having ordinary skill in the art to which said subject matter pertains. Patentability shall not be negatived by the manner in which the invention was made.

This application currently names joint Inventors. In considering patentability of the claims under 35 U.S.C. 103(a), the Examiner presumes that the subject matter of the various claims was commonly owned at the time any inventions covered therein were made absent any evidence to the contrary. The Applicant is advised of the obligation under 37 CFR 1.56 to point out the Inventor and invention dates of each claim that was not commonly owned at the time a later invention was made in order for the examiner to consider the applicability of 35 U.S.C. 103(c) and potential 35 U.S.C. 102(e), (f) or (g) prior art under 35 U.S.C. 103(a).

Application/Control Number: 09/830,666

Art Unit: 3762

11. Claims 22-27 are rejected under 35 U.S.C. 103(a) as being unpatentable over Boveja et al. (US 6505074) in view or Gross et al. (US 6354991) and further in view of Durand et al. (US 6587725).

Boveja et al. disclose a method for electrical neural stimulation to treat urinary incontinence (abstract; col. 1 @ 33- col. 2 @ 38; col. 3 @ 15-32; col. 4 @ 25-30; col. 5 @ 4-6; col. 7 @ 59 - col. 8 @ 11; col. 10 @ 5-48; col. 12 @ 13-21).

As discussed in the previous paragraph of this action, Boveja et al. disclose the claimed invention except for detecting a bladder event from neural signals and stimulating nerves in response to the detected event.

Gross et al. disclose an incontinence treatment device and teach signal detection (EMG and non-EMG signals) indicative of abdominal stress/ a bladder event for the purpose of responding to the patient's current bladder condition, potentially treating the patient by stimulating muscles/ nerves to inhibit involuntary urine flow. It would have been obvious to one having ordinary skill in the art at the time of the invention to have used signal detection indicative of a bladder event in the Boveja et al. system in order to provide treatment that is optimized based on the patient's current condition, rather than using a preprogrammed stimulation treatment program, so the treatment is responsive to improvements/ changes in the patient's condition over time (abstract; col. 3 @ 33- col. 4 @ 15; col. 4 @ 36-41 and 46-59; col. 9 @ 30-44; col. 10 @ 57-61; col. 14 @ 39-54).

As discussed in the previous paragraph of this action, modified Boveja et al. disclose the claimed invention except for detecting a bladder event from a nerve signals.

Application/Control Number: 09/830,666

Art Unit: 3762

Durand et al. disclose a closed loop stimulation device and teach detection of a nerve signal for the purpose of responding to the patient's current condition, potentially treating the patient by nerve stimulation. It would have been obvious to one having ordinary skill in the art at the time of the invention to have used a detected nerve signal to control the treatment in the modified Boveja et al. system in order use a signal electrode element to provide both sensing and stimulation to minimize the complexity of the implanted system (abstact; figure 5; col. 7 @ 38-57)

12. Claims 28 and 29 are rejected under 35 U.S.C. 103(a) as being unpatentable over Boveja et al. (US 6505074) in view or Gross et al. (US 6354991) and further in view of Durand et al. (US 6587725) and further in view of Fang et al. (US 5199430). As discussed in paragraph 11 of this action, modified Boveja et al. disclose the claimed invention except for the detecting and stimulation electrode being located on the extradural sacral nerve root of the group of S2-S4.

Fang et al. teaches bladder nerve stimulation using stimulation electrodes located on the extradural sacral nerve root of the group of S2-S4 for the purpose of providing nerve stimulation treatment to treat uninary incontinence. It would have been obvious to one having ordinary skill in the art at the time of the invention to have placed the electrodes on the extradural sacral nerve root of the group of S2-S4 in the modified Boveja et al. system in order to detect and stimulate nerves using a point known to be associated with bladder control to ensure effective sensing and effective stimulation treatment (abstract; figure 1; col.1 @ 12-38; col. 2 @ 48-64; col. 4 @ 15-28).

# Page 10

### Conclusion

Any inquiry concerning this communication or earlier communications from the Examiner should be directed to Fran Oropeza, telephone number is (703) 605-4355. The Examiner can normally be reached on Monday – Thursday from 6 a.m. to 4:30 p.m.

If attempts to reach the Examiner by telephone are unsuccessful, the Examiner's Supervisor, Angela D. Sykes can be reached on (703) 308-5181. The fax phone number for the organization where this application or proceeding is assigned is (703) 306-4520 for regular communication and for After Final communications.

Any inquiry of a general nature or relating to the status of this application or proceeding should be directed to the Receptionist, telephone number is (703) 308-0858.

Frances P. Oropeza Patent Examiner

Art Unit 3762

x/21/03

ANGELA D. SYKES SUPERVISORY PATENT EXAMINER TECHNOLOGY CENTER 3700

Cengel D. Ash